OSE Immunotherapeutics SA (EPA:OSE)

OSE Immunotherapeutics Revenue

In the year 2025, OSE Immunotherapeutics had annual revenue of 1.78M EUR, down -97.86%. OSE Immunotherapeutics had revenue of 862.00K in the half year ending December 31, 2024, a decrease of -61.77%.

• Revenue: 1.78M
• Revenue Growth: -95.84%
• P/S Ratio: 46.50
• Revenue / Employee: 27.84K
• Employees: 64
• Market Cap: 82.87M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.78M	-81.65M	-97.86%
Dec 31, 2024	83.44M	81.21M	3,646.52%
Dec 31, 2023	2.23M	-16.08M	-87.83%
Dec 31, 2022	18.30M	-8.00M	-30.43%
Dec 31, 2021	26.31M	15.89M	152.48%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2024

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 31, 2026

Data Sources Report a data error